{"id":"58e0d5c7-82a7-5ab3-a0db-c57880feddb7","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-pad-markers","predicate":"does_not_reliably_improve","statement":"Plasma arginine rose, but NO-related measurements were reduced or unimproved versus placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"6e026fac-4504-5f44-8226-6b8be66321f1","mechanism_event_label":"Higher blood availability did not ensure better pathway output.","subject":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"object":{"id":"3b11daa2-3e58-5d85-9039-99cb0bc870cd","slug":"pad-no-availability-markers","display_name":"NO availability markers in peripheral arterial disease","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6e026fac-4504-5f44-8226-6b8be66321f1","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-pad-markers-event","event_type":"observed_relationship","label":"Higher blood availability did not ensure better pathway output.","description":"Plasma arginine rose, but NO-related measurements were reduced or unimproved versus placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3b11daa2-3e58-5d85-9039-99cb0bc870cd","slug":"pad-no-availability-markers","display_name":"NO availability markers in peripheral arterial disease","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"4337f035-2769-539a-80a5-d9e320ea292a","slug":"circulating-arginine-concentration","display_name":"Circulating arginine concentration","entity_type_key":"cellular_process"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"NO-PAIN: 133 PAD patients, 3 g/day for six months.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Endpoint-dependent pattern; not every marker necessarily decreased.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Arginine collection; tissue, species, dose and formulation distinctions retained.","comparator":null,"unit":null,"notes":"","entity":{"slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Higher blood availability did not ensure better pathway output.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17592080/ · DOI 10.1161/circulationaha.106.683656","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"087c4e83-1a6c-5b5e-9c67-e4cf25870dd8","evidence_kind":"source_excerpt","locator":"Lines 390-396","start_line":390,"end_line":396,"excerpt":"## arg-pad-markers\nHigher blood availability did not ensure better pathway output.\nPlasma arginine rose, but NO-related measurements were reduced or unimproved versus placebo.\nModel: NO-PAIN: 133 PAD patients, 3 g/day for six months.\nLimitations: Endpoint-dependent pattern; not every marker necessarily decreased.\nEvidence access: Primary abstract\nL-arginine supplementation in peripheral arterial disease: no benefit and possible harm. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17592080/ · DOI 10.1161/circulationaha.106.683656","model_system":"NO-PAIN: 133 PAD patients, 3 g/day for six months.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; primary evidence access stated per claim.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"bb9a67ea-904f-5b8a-93a4-459081212bdd","stable_key":"import-fd37d270-3395-56d6-9f1c-ddda56e606f6","title":"L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"ec0e9a3fb72b7485534e4372a074ac7624a399ff962e55690eb462217b5149ec","revision_id":"af027270-5535-51ae-85ff-9c76c518c962","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}